Autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia and renal cell carcinoma after treatment with high-dose intravenous bolus interleukin-2.
Schlegel
P J
PJ
Samlowski
W E
WE
Ward
J H
JH
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use; D000368:Aged; D000744:Anemia, Hemolytic, Autoimmune / Q000209:etiology*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000150:complications* / Q000188:drug therapy; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000150:complications / Q000188:drug therapy; D011994:Recombinant Proteins / Q000009:adverse effects* / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D007376:Interleukin-2; D011994:Recombinant Proteins; C082598:aldesleukin